Comparison of Estimated Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Through Commercial Laboratory Residual Sera Testing and a Community Survey
Kristina L. Bajema, F. Scott Dahlgren, Travis Lim, Nicolette Bestul, Holly M. Biggs, Jacqueline E. Tate, Claudio Owusu, Christine M. Szablewski, Cherie Drenzek, Jan Drobeniuc, Vera Semenova, Li Han, Peter Browning, Rita Desai, Monica Epperson, Lily Jia, Natalie J. Thornburg, Chris Edens, Alicia M. Fry, Aron J. Hall, Jarad Schiffer, Fiona P. Havers
Abstract
We compared severe acute respiratory syndrome coronavirus 2 seroprevalence estimated from commercial laboratory residual sera and a community household survey in metropolitan Atlanta during April and May 2020 and found these 2 estimates to be similar (4.94% vs 3.18%). Compared with more representative surveys, commercial sera can provide an approximate measure of seroprevalence.
Topics & Concepts
SeroprevalenceMedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Respiratory systemAtlantaMetropolitan areaCoronavirus disease 2019 (COVID-19)ResidualVirologyInternal medicineEnvironmental healthImmunologySerologyAntibodyPathologyDiseaseInfectious disease (medical specialty)Computer scienceAlgorithmCOVID-19 epidemiological studiesSARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testing